[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100544111":3},{"organization":4,"armGroups":7,"interventions":22,"overallOfficials":60,"centralContacts":64,"locations":74,"responsibleParty":709,"collaborators":711,"id":748,"slug":749,"hasResults":750,"nctId":751,"briefTitle":752,"officialTitle":753,"acronym":754,"eligibilityCriteria":755,"healthyVolunteers":750,"sex":756,"minAge":757,"maxAge":68,"enrollmentInfo":758,"targetDuration":68,"studyType":761,"phases":762,"briefSummary":764,"conditions":765,"keywords":768,"overallStatus":124,"whyStopped":68,"lastUpdateSubmitDate":773,"lastUpdatePostDateStruct":774,"startDateStruct":777,"completionDateStruct":779,"leadSponsor":781,"locationsCount":782},{"fullName":5,"class":6},"Gustave Roussy, Cancer Campus, Grand Paris","OTHER",[8,14],{"label":9,"type":6,"description":10,"interventionNames":11},"Arm A: ICI - ICI Combination","Nivolumab (3 mg\u002Fkg infusion, every 3 weeks) x 4 doses + ipilimumab (1 mg\u002Fkg infusion, every 3 weeks) x 4 doses. At the end of the 4 injections carried out 21 days apart and in the absence of limiting side effects or progression justifying the cessation of the treatment according to the investigating doctor, maintenance treatment with nivolumab will be continued, at a rate of one injection every 2 weeks at a dose of 240 mg or every 4 weeks at a dose of 480 mg depending on the choice of the investigating doctor. Nivolumab will be administered for a maximum of 2 years.\n\nPatients are required to receive all four doses of NIVO+IPI before beginning NIVO monotherapy except for ipilimumab-induced toxicity compatible with nivolumab maintenance.",[12,13],"Drug: Nivolumab","Drug: Ipilimumab",{"label":15,"type":6,"description":16,"interventionNames":17},"Arm B: VEGFR-TKI- ICI arm (axitinib + pembrolizumab)","Investigator's choice between:\n\n* Axitinib (5 mg oral twice a day) + pembrolizumab (200 mg flat IV every 3 weeks or 400 mg flat IV every 6 weeks).\n* Cabozantinib (40 mg oral, once a day away from meals) + nivolumab infusion (480 mg flat dose every 4 weeks)\n* Lenvatinib (20 mg oral, once a day) + pembrolizumab (200 mg flat IV every 3 weeks or 400 mg flat IV every 6 weeks)",[12,18,19,20,21],"Drug: Pembrolizumab","Drug: Cabozantinib","Drug: Axitinib","Drug: Lenvatinib",[23,30,36,42,48,54],{"type":24,"name":25,"description":26,"armGroupLabels":27,"otherNames":28},"DRUG","Nivolumab","Briefly, nivolumab is administered as an approximately 30-minute (240mg every 2 weeks) or 60-minute (480mg every 4 weeks) IV infusion. Nivolumab is to be administered first. The nivolumab infusion must be promptly followed by a saline flush to clear the line of nivolumab before starting the ipilimumab infusion.",[9,15],[29],"OPDIVO",{"type":24,"name":31,"description":32,"armGroupLabels":33,"otherNames":34},"Ipilimumab","The second infusion will always be ipilimumab and will start at least 30 minutes after completion of the nivolumab infusion. Ipilimumab is to be administered as an approximately 30-minute IV infusion.\n\nWhen administered together, nivolumab and ipilimumab will be administered on Day 1 of each 21-day cycle.",[9],[35],"YERVOY",{"type":24,"name":37,"description":38,"armGroupLabels":39,"otherNames":40},"Pembrolizumab","Pembrolizumab is to be administered as an approximately 30-minute IV infusion.",[15],[41],"KEYTRUDA",{"type":24,"name":43,"description":44,"armGroupLabels":45,"otherNames":46},"Cabozantinib","Cabozantinib is a medication that is taken orally every day, once a day away from meals at the initial dose of 40 mg\u002Fday.",[15],[47],"CABOMETYX",{"type":24,"name":49,"description":50,"armGroupLabels":51,"otherNames":52},"Axitinib","Axitinib is a medication that is taken orally every day, 2 times a day continuously, at the starting dose of 5mg x2\u002Fday.",[15],[53],"INLYTA",{"type":24,"name":55,"description":56,"armGroupLabels":57,"otherNames":58},"Lenvatinib","Lenvatinib is a medication that is taken orally every day, once a day at the initial dose of 20mg\u002Fday.",[15],[59],"LENVIMA",[61],{"name":62,"affiliation":5,"role":63},"Laurence ALBIGES, MD, PhD","STUDY_CHAIR",[65,70],{"name":62,"role":66,"phone":67,"phoneExt":68,"email":69},"CONTACT","+33 (0)1 42 11 66 90",null,"laurence.albiges@gustaveroussy.fr",{"name":71,"role":66,"phone":72,"phoneExt":68,"email":73},"Maia CLAVEAU","+33 (0)1 42 11 53 49","Maia.CLAVEAU@gustaveroussy.fr",[75,93,108,122,137,151,167,178,192,206,220,234,248,262,276,290,304,318,332,346,360,374,388,402,416,430,444,455,466,477,488,502,516,530,544,558,570,584,598,612,626,640,654,668,682,693],{"facility":76,"status":77,"city":78,"state":68,"zip":79,"country":80,"countryCode":81,"cosmosGeoPoint":82,"geoPoint":87,"contacts":88},"Medical University of Vienna","NOT_YET_RECRUITING","Vienna","1090","Austria","AT",{"type":83,"coordinates":84},"Point",[85,86],16.37208,48.20849,{"lat":86,"lon":85},[89],{"name":90,"role":66,"phone":91,"phoneExt":68,"email":92},"Manuela Schmidinger, MD","+43 69910710844","manuela.schimidinger@meduniwien.ac.at",{"facility":94,"status":77,"city":95,"state":68,"zip":96,"country":97,"countryCode":68,"cosmosGeoPoint":98,"geoPoint":102,"contacts":103},"Masarykův onkologický ústav, Masaryk Memorial Cancer Institute (MOU)","Brno","65653","Czechia",{"type":83,"coordinates":99},[100,101],16.60796,49.19522,{"lat":101,"lon":100},[104],{"name":105,"role":66,"phone":106,"phoneExt":68,"email":107},"Alexandr Poprach, MD, PhD","+420 543136831","poprach@mou.cz",{"facility":109,"status":77,"city":110,"state":68,"zip":111,"country":97,"countryCode":68,"cosmosGeoPoint":112,"geoPoint":116,"contacts":117},"Fakultní nemocnice Hradec Králová, University Hospital Hradec Kralove (FNHK)","Hradec Králové","50005",{"type":83,"coordinates":113},[114,115],15.83277,50.20923,{"lat":115,"lon":114},[118],{"name":119,"role":66,"phone":120,"phoneExt":68,"email":121},"Jindřich Kopecký, MD, PhD","+420 495834980","jindrich.kopecky@fnhj.cz",{"facility":123,"status":124,"city":125,"state":68,"zip":126,"country":97,"countryCode":68,"cosmosGeoPoint":127,"geoPoint":131,"contacts":132},"Fakultní nemocnice Olomouc, University Hospital Olomouc (FNOL)","RECRUITING","Olomouc","77900",{"type":83,"coordinates":128},[129,130],17.25175,49.59552,{"lat":130,"lon":129},[133],{"name":134,"role":66,"phone":135,"phoneExt":68,"email":136},"Hana Študentová, MD","+420 588 441 111","hana.studentova@fnol.cz",{"facility":138,"status":77,"city":139,"state":68,"zip":140,"country":97,"countryCode":68,"cosmosGeoPoint":141,"geoPoint":145,"contacts":146},"Fakultní nemocnice v Motole, University Hospital Motol (MOTOL)","Prague","15000",{"type":83,"coordinates":142},[143,144],14.42076,50.08804,{"lat":144,"lon":143},[147],{"name":148,"role":66,"phone":149,"phoneExt":68,"email":150},"Tomáš Büchler, MD, PhD","+420 224439427","tomas.buchler@fnmotol.cz",{"facility":152,"status":124,"city":153,"state":68,"zip":154,"country":155,"countryCode":156,"cosmosGeoPoint":157,"geoPoint":161,"contacts":162},"Institut de Cancérologie de l'Ouest - Angers","Angers","49055","France","FR",{"type":83,"coordinates":158},[159,160],-0.55202,47.47156,{"lat":160,"lon":159},[163],{"name":164,"role":66,"phone":165,"phoneExt":68,"email":166},"Elouen BOUGHALEM, MD","+33241352700","elouen.boughalem@ico.unicancer.fr",{"facility":168,"status":124,"city":153,"state":68,"zip":169,"country":155,"countryCode":156,"cosmosGeoPoint":170,"geoPoint":172,"contacts":173},"CHU Angers","49933",{"type":83,"coordinates":171},[159,160],{"lat":160,"lon":159},[174],{"name":175,"role":66,"phone":176,"phoneExt":68,"email":177},"Pierre BIGOT, MD, PhD","+33 241356196","pibigot@chu-angers.fr",{"facility":179,"status":124,"city":180,"state":68,"zip":181,"country":155,"countryCode":156,"cosmosGeoPoint":182,"geoPoint":186,"contacts":187},"Institut Sainte Catherine","Avignon","84000",{"type":83,"coordinates":183},[184,185],4.80892,43.94834,{"lat":185,"lon":184},[188],{"name":189,"role":66,"phone":190,"phoneExt":68,"email":191},"Bertrand BILLEMONT, MD","+33 490276231","b.billemont@isc84.org",{"facility":193,"status":124,"city":194,"state":68,"zip":195,"country":155,"countryCode":156,"cosmosGeoPoint":196,"geoPoint":200,"contacts":201},"CH de la Côte Basque","Bayonne","64100",{"type":83,"coordinates":197},[198,199],-1.473,43.49316,{"lat":199,"lon":198},[202],{"name":203,"role":66,"phone":204,"phoneExt":68,"email":205},"Louis FRANCOIS, MD","+33 559443535","lfrancois@ch-cotebasque.fr",{"facility":207,"status":124,"city":208,"state":68,"zip":209,"country":155,"countryCode":156,"cosmosGeoPoint":210,"geoPoint":214,"contacts":215},"Hôpital Jean Minjoz","Besançon","25030",{"type":83,"coordinates":211},[212,213],6.01815,47.24878,{"lat":213,"lon":212},[216],{"name":217,"role":66,"phone":218,"phoneExt":68,"email":219},"Fabien CALCAGNO, MD","+33 370632403","fabien.calcagno@gmail.com",{"facility":221,"status":77,"city":222,"state":68,"zip":223,"country":155,"countryCode":156,"cosmosGeoPoint":224,"geoPoint":228,"contacts":229},"CHU de Bordeaux Hôpital Saint-André","Bordeaux","33000",{"type":83,"coordinates":225},[226,227],-0.58046,44.84124,{"lat":227,"lon":226},[230],{"name":231,"role":66,"phone":232,"phoneExt":68,"email":233},"Felix LEFORT, MD","+33 556795808","felix.lefort@chu-bordeaux.fr",{"facility":235,"status":124,"city":236,"state":68,"zip":237,"country":155,"countryCode":156,"cosmosGeoPoint":238,"geoPoint":242,"contacts":243},"Centre François Baclesse","Caen","14076",{"type":83,"coordinates":239},[240,241],-0.35912,49.18585,{"lat":241,"lon":240},[244],{"name":245,"role":66,"phone":246,"phoneExt":68,"email":247},"Florence JOLY, MD, PhD","+33 231455002","f.joly@baclesse.unicancer.fr",{"facility":249,"status":77,"city":250,"state":68,"zip":251,"country":155,"countryCode":156,"cosmosGeoPoint":252,"geoPoint":256,"contacts":257},"CH Châlon Sur Saône","Chalon-sur-Saône","71321",{"type":83,"coordinates":253},[254,255],4.85372,46.78112,{"lat":255,"lon":254},[258],{"name":259,"role":66,"phone":260,"phoneExt":68,"email":261},"Axelle BOUDRANT, MD","+33 385910045","axelle.boudrant@ch-chalon71.fr",{"facility":263,"status":77,"city":264,"state":68,"zip":265,"country":155,"countryCode":156,"cosmosGeoPoint":266,"geoPoint":270,"contacts":271},"Centre Jean Perrin","Clermont-Ferrand","63011",{"type":83,"coordinates":267},[268,269],3.08682,45.77969,{"lat":269,"lon":268},[272],{"name":273,"role":66,"phone":274,"phoneExt":68,"email":275},"Hakim MAHAMMEDI, MD","+33 473278080","hakim.mahammedi@clermont.unicancer.fr",{"facility":277,"status":124,"city":278,"state":68,"zip":279,"country":155,"countryCode":156,"cosmosGeoPoint":280,"geoPoint":284,"contacts":285},"Hôpital Henri Mondor","Créteil","94000",{"type":83,"coordinates":281},[282,283],2.46569,48.79266,{"lat":283,"lon":282},[286],{"name":287,"role":66,"phone":288,"phoneExt":68,"email":289},"Christophe TOURNIGAND, MD, PhD","+33 149812567","christophe.tournigand@aphp.fr",{"facility":291,"status":124,"city":292,"state":68,"zip":293,"country":155,"countryCode":156,"cosmosGeoPoint":294,"geoPoint":298,"contacts":299},"Centre Georges-François Leclerc","Dijon","21079",{"type":83,"coordinates":295},[296,297],5.01391,47.31344,{"lat":297,"lon":296},[300],{"name":301,"role":66,"phone":302,"phoneExt":68,"email":303},"Sylvain LADOIRE, MD, PhD","+33 380737506","sladoire@cgfl.fr",{"facility":305,"status":124,"city":306,"state":68,"zip":307,"country":155,"countryCode":156,"cosmosGeoPoint":308,"geoPoint":312,"contacts":313},"CHU Grenoble","Grenoble","38043",{"type":83,"coordinates":309},[310,311],5.71479,45.17869,{"lat":311,"lon":310},[314],{"name":315,"role":66,"phone":316,"phoneExt":68,"email":317},"Mathieu LARAMAS, MD","+33476765451","mlaramas@chu-grenoble.fr",{"facility":319,"status":124,"city":320,"state":68,"zip":321,"country":155,"countryCode":156,"cosmosGeoPoint":322,"geoPoint":326,"contacts":327},"CHD Vendée","La Roche-sur-Yon","85925",{"type":83,"coordinates":323},[324,325],-1.42757,46.66974,{"lat":325,"lon":324},[328],{"name":329,"role":66,"phone":330,"phoneExt":68,"email":331},"Charlotte GREILSAMER, MD","+33 251446173","charlotte.greilsamer@ght85.fr",{"facility":333,"status":77,"city":334,"state":68,"zip":335,"country":155,"countryCode":156,"cosmosGeoPoint":336,"geoPoint":340,"contacts":341},"Centre Oscar Lambret","Lille","59000",{"type":83,"coordinates":337},[338,339],3.05512,50.63391,{"lat":339,"lon":338},[342],{"name":343,"role":66,"phone":344,"phoneExt":68,"email":345},"Diane PANNIER, MD","+33 320295959","d-pannier@o-lambret.fr",{"facility":347,"status":124,"city":348,"state":68,"zip":349,"country":155,"countryCode":156,"cosmosGeoPoint":350,"geoPoint":354,"contacts":355},"Polyclinique de Limoges","Limoges","87000",{"type":83,"coordinates":351},[352,353],1.24759,45.83362,{"lat":353,"lon":352},[356],{"name":357,"role":66,"phone":358,"phoneExt":68,"email":359},"Sabrina FALKOWSKI, MD","+33 555454800","sf@imagerned-87.com",{"facility":361,"status":77,"city":362,"state":68,"zip":363,"country":155,"countryCode":156,"cosmosGeoPoint":364,"geoPoint":368,"contacts":369},"Centre Léon Bérard","Lyon","69008",{"type":83,"coordinates":365},[366,367],4.84789,45.74906,{"lat":367,"lon":366},[370],{"name":371,"role":66,"phone":372,"phoneExt":68,"email":373},"Armelle VINCENEUX, MD","+33 426556833","armelle.vinceneux@lyon.unicancer.fr",{"facility":375,"status":124,"city":376,"state":68,"zip":377,"country":155,"countryCode":156,"cosmosGeoPoint":378,"geoPoint":382,"contacts":383},"Institut Paoli-Calmettes","Marseille","13009",{"type":83,"coordinates":379},[380,381],5.38107,43.29695,{"lat":381,"lon":380},[384],{"name":385,"role":66,"phone":386,"phoneExt":68,"email":387},"Gwenaelle GRAVIS, MD","+33 491223740","gravisg@ipc.unicancer.fr",{"facility":389,"status":124,"city":390,"state":68,"zip":391,"country":155,"countryCode":156,"cosmosGeoPoint":392,"geoPoint":396,"contacts":397},"Institut Régional du Cancer de Montpellier","Montpellier","34298",{"type":83,"coordinates":393},[394,395],3.87635,43.61093,{"lat":395,"lon":394},[398],{"name":399,"role":66,"phone":400,"phoneExt":68,"email":401},"Diego TOSI, MD, PhD","+33 467612304","diego.tosi@icm.unicancer.fr",{"facility":403,"status":124,"city":404,"state":68,"zip":405,"country":155,"countryCode":156,"cosmosGeoPoint":406,"geoPoint":410,"contacts":411},"Centre Antoine Lacassagne","Nice","06189",{"type":83,"coordinates":407},[408,409],7.26608,43.70313,{"lat":409,"lon":408},[412],{"name":413,"role":66,"phone":414,"phoneExt":68,"email":415},"Delphine BORCHIELLINI, MD","+33 4 92 03 15 14","Delphine.borchiellini@nice.unicancer.fr",{"facility":417,"status":124,"city":418,"state":68,"zip":419,"country":155,"countryCode":156,"cosmosGeoPoint":420,"geoPoint":424,"contacts":425},"CHU de Nîmes","Nîmes","30029",{"type":83,"coordinates":421},[422,423],4.35788,43.83665,{"lat":423,"lon":422},[426],{"name":427,"role":66,"phone":428,"phoneExt":68,"email":429},"Nadine HOUEDE, MD, PhD","+33 466683231","nadine.houede@chu-nimes.fr",{"facility":431,"status":77,"city":432,"state":68,"zip":433,"country":155,"countryCode":156,"cosmosGeoPoint":434,"geoPoint":438,"contacts":439},"Hôpital de la Pitié Salpêtrière","Paris","75013",{"type":83,"coordinates":435},[436,437],2.3488,48.85341,{"lat":437,"lon":436},[440],{"name":441,"role":66,"phone":442,"phoneExt":68,"email":443},"Loïc JAFFRELOT, MD","+33 142160507","loic.jaffrelot@aphp.fr",{"facility":445,"status":77,"city":432,"state":68,"zip":446,"country":155,"countryCode":156,"cosmosGeoPoint":447,"geoPoint":449,"contacts":450},"Hôpital Bichat - Claude Bernard","75018",{"type":83,"coordinates":448},[436,437],{"lat":437,"lon":436},[451],{"name":452,"role":66,"phone":453,"phoneExt":68,"email":454},"Idir OUZAID, MD, PhD","+33 140258935","idir.ouzaid@aphp.fr",{"facility":456,"status":124,"city":432,"state":68,"zip":457,"country":155,"countryCode":156,"cosmosGeoPoint":458,"geoPoint":460,"contacts":461},"Hôpital Tenon","75020",{"type":83,"coordinates":459},[436,437],{"lat":437,"lon":436},[462],{"name":463,"role":66,"phone":464,"phoneExt":68,"email":465},"Ahmed KHALIL, MD","+33 611174284","ahmed.khalil@aphp.fr",{"facility":467,"status":124,"city":432,"state":68,"zip":468,"country":155,"countryCode":156,"cosmosGeoPoint":469,"geoPoint":471,"contacts":472},"Hôpital Saint-Louis","75475",{"type":83,"coordinates":470},[436,437],{"lat":437,"lon":436},[473],{"name":474,"role":66,"phone":475,"phoneExt":68,"email":476},"Clément DUMONT, MD","+33142494217","clement.dumont@aphp.fr",{"facility":478,"status":124,"city":432,"state":68,"zip":479,"country":155,"countryCode":156,"cosmosGeoPoint":480,"geoPoint":482,"contacts":483},"Institut Mutualiste Montsouris","75674",{"type":83,"coordinates":481},[436,437],{"lat":437,"lon":436},[484],{"name":485,"role":66,"phone":486,"phoneExt":68,"email":487},"Mostefa BENNAMOUN, md","+33 156616241","mostefa.bennamoun@imm.fr",{"facility":489,"status":124,"city":490,"state":68,"zip":491,"country":155,"countryCode":156,"cosmosGeoPoint":492,"geoPoint":496,"contacts":497},"CH de Pau","Pau","64000",{"type":83,"coordinates":493},[494,495],-0.35583,43.31117,{"lat":495,"lon":494},[498],{"name":499,"role":66,"phone":500,"phoneExt":68,"email":501},"Kévin BOURCIER, MD","+33 559727608","kevin.bourcier@ch-pau.fr",{"facility":503,"status":124,"city":504,"state":68,"zip":505,"country":155,"countryCode":156,"cosmosGeoPoint":506,"geoPoint":510,"contacts":511},"Hospices Civils de Lyon","Pierre-Bénite","69310",{"type":83,"coordinates":507},[508,509],4.82424,45.70359,{"lat":509,"lon":508},[512],{"name":513,"role":66,"phone":514,"phoneExt":68,"email":515},"Denis MAILLET, MD","+33478861771","denis.maillet@chu-lyon.fr",{"facility":517,"status":124,"city":518,"state":68,"zip":519,"country":155,"countryCode":156,"cosmosGeoPoint":520,"geoPoint":524,"contacts":525},"CHU Poitiers","Poitiers","86021",{"type":83,"coordinates":521},[522,523],0.34348,46.58261,{"lat":523,"lon":522},[526],{"name":527,"role":66,"phone":528,"phoneExt":68,"email":529},"Sheik EMAMBUX, MD","+33 549444279","sheik.emambux@chu-poitiers.fr",{"facility":531,"status":124,"city":532,"state":68,"zip":533,"country":155,"countryCode":156,"cosmosGeoPoint":534,"geoPoint":538,"contacts":539},"Institut Godinot","Reims","51100",{"type":83,"coordinates":535},[536,537],4.02853,49.26526,{"lat":537,"lon":536},[540],{"name":541,"role":66,"phone":542,"phoneExt":68,"email":543},"Jean-Christophe EYMARD, MD","+33 326504382","jeanchristophe.eymard@reims.unicancer.fr",{"facility":545,"status":124,"city":546,"state":68,"zip":547,"country":155,"countryCode":156,"cosmosGeoPoint":548,"geoPoint":552,"contacts":553},"Centre Eugène Marquis","Rennes","35042",{"type":83,"coordinates":549},[550,551],-1.67431,48.11109,{"lat":551,"lon":550},[554],{"name":555,"role":66,"phone":556,"phoneExt":68,"email":557},"Brigitte LAGUERRE, MD","+33299253182","b.laguerre@rennes.unicancer.fr",{"facility":559,"status":77,"city":560,"state":68,"zip":561,"country":155,"countryCode":156,"cosmosGeoPoint":562,"geoPoint":566,"contacts":567},"CHU Saint-Etienne","Saint-Etienne","42270",{"type":83,"coordinates":563},[564,565],4.39,45.43389,{"lat":565,"lon":564},[568],{"name":513,"role":66,"phone":569,"phoneExt":68,"email":515},"+33 4 78 86 17 71",{"facility":571,"status":124,"city":572,"state":68,"zip":573,"country":155,"countryCode":156,"cosmosGeoPoint":574,"geoPoint":578,"contacts":579},"Institut de Cancérologie de l'Ouest - Saint Herblain","Saint-Herblain","44806",{"type":83,"coordinates":575},[576,577],-1.651,47.21154,{"lat":577,"lon":576},[580],{"name":581,"role":66,"phone":582,"phoneExt":68,"email":583},"Frédéric ROLLAND, MD","+33 (0)2 40 67 99 00","frederic.rolland@ico.unicancer.fr",{"facility":585,"status":124,"city":586,"state":68,"zip":587,"country":155,"countryCode":156,"cosmosGeoPoint":588,"geoPoint":592,"contacts":593},"HIA Bégin","Saint-Mandé","94160",{"type":83,"coordinates":589},[590,591],2.41579,48.83864,{"lat":591,"lon":590},[594],{"name":595,"role":66,"phone":596,"phoneExt":68,"email":597},"Carole HELISSEY, MD","+33143985319","carole.helissey@gmail.com",{"facility":599,"status":124,"city":600,"state":68,"zip":601,"country":155,"countryCode":156,"cosmosGeoPoint":602,"geoPoint":606,"contacts":607},"CHU Sud Réunion","Saint-Pierre","97448",{"type":83,"coordinates":603},[604,605],5.40682,43.29282,{"lat":605,"lon":604},[608],{"name":609,"role":66,"phone":610,"phoneExt":68,"email":611},"Mohamed KHETTAB, MD","+262 262359000","mohamed.khettab@chu-reunion.fr",{"facility":613,"status":124,"city":614,"state":68,"zip":615,"country":155,"countryCode":156,"cosmosGeoPoint":616,"geoPoint":620,"contacts":621},"Institut de cancérologie Strasbourg Europe","Strasbourg","67200",{"type":83,"coordinates":617},[618,619],7.74553,48.58392,{"lat":619,"lon":618},[622],{"name":623,"role":66,"phone":624,"phoneExt":68,"email":625},"Philippe BARTHELEMY, MD","+33 368766767","p.barthelemy@icans.eu",{"facility":627,"status":124,"city":628,"state":68,"zip":629,"country":155,"countryCode":156,"cosmosGeoPoint":630,"geoPoint":634,"contacts":635},"Hôpital Foch","Suresnes","92150",{"type":83,"coordinates":631},[632,633],2.22929,48.87143,{"lat":633,"lon":632},[636],{"name":637,"role":66,"phone":638,"phoneExt":68,"email":639},"Raffaele RATTA, MD","+33 146253581","r.ratta@hopital-foch.com",{"facility":641,"status":124,"city":642,"state":68,"zip":643,"country":155,"countryCode":156,"cosmosGeoPoint":644,"geoPoint":648,"contacts":649},"Oncopole Claudius Regaud - IUCT-Oncopole","Toulouse","31059",{"type":83,"coordinates":645},[646,647],1.44367,43.60426,{"lat":647,"lon":646},[650],{"name":651,"role":66,"phone":652,"phoneExt":68,"email":653},"Damien POUESSEL, MD, PhD","+33 531155993","pouessel.damien@iuct-oncopole.fr",{"facility":655,"status":124,"city":656,"state":68,"zip":657,"country":155,"countryCode":156,"cosmosGeoPoint":658,"geoPoint":662,"contacts":663},"Hôpital Bretonneau","Tours","37044",{"type":83,"coordinates":659},[660,661],0.70398,47.39484,{"lat":661,"lon":660},[664],{"name":665,"role":66,"phone":666,"phoneExt":68,"email":667},"Mathilde CANCEL, MD","+33 247479919","m.cancel@chu-tours.fr",{"facility":669,"status":124,"city":670,"state":68,"zip":671,"country":155,"countryCode":156,"cosmosGeoPoint":672,"geoPoint":676,"contacts":677},"Institut de Cancérologie de Lorraine","Vandœuvre-lès-Nancy","54519",{"type":83,"coordinates":673},[674,675],6.17114,48.66115,{"lat":675,"lon":674},[678],{"name":679,"role":66,"phone":680,"phoneExt":68,"email":681},"Lionel GEOFFROIS, MD","+33 3 83 59 84 61","l.geoffrois@nancy.unicancer.fr",{"facility":683,"status":124,"city":684,"state":68,"zip":685,"country":155,"countryCode":156,"cosmosGeoPoint":686,"geoPoint":690,"contacts":691},"Gustave Roussy","Villejuif","94805",{"type":83,"coordinates":687},[688,689],2.35992,48.7939,{"lat":689,"lon":688},[692],{"name":62,"role":66,"phone":67,"phoneExt":68,"email":69},{"facility":694,"status":77,"city":695,"state":68,"zip":696,"country":697,"countryCode":698,"cosmosGeoPoint":699,"geoPoint":703,"contacts":704},"Antoni van Leeuwenhoek","Amsterdam","1066CX","Netherlands","NL",{"type":83,"coordinates":700},[701,702],4.88969,52.37403,{"lat":702,"lon":701},[705],{"name":706,"role":66,"phone":707,"phoneExt":68,"email":708},"Sofie Wilgenhof, MD","+31 020 512 9111","s.wilgenhof@nki.nl",{"type":710,"investigatorFullName":68,"investigatorTitle":68,"investigatorAffiliation":68,"oldNameTitle":68,"oldOrganization":68},"SPONSOR",[712,714,717,720,722,724,726,728,730,732,734,735,737,739,741,744,746],{"name":713,"class":6},"European Commission",{"name":715,"class":716},"CRIS Cancer Foundation","UNKNOWN",{"name":718,"class":719},"National Cancer Institute, France","OTHER_GOV",{"name":721,"class":6},"Rennes University Hospital",{"name":723,"class":6},"University Hospital, Essen",{"name":725,"class":716},"Fundació Privada Institut d'Investigació Oncològica de Vall d'Hebron",{"name":727,"class":6},"The Netherlands Cancer Institute",{"name":729,"class":6},"Servicio Madrileño de Salud, Madrid, Spain",{"name":731,"class":6},"Hospital Universitario 12 de Octubre",{"name":733,"class":6},"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano",{"name":76,"class":6},{"name":736,"class":716},"FAKULTNI NEMOCNICE OLOMOUC",{"name":738,"class":716},"International Kidney Cancer Coalition",{"name":740,"class":716},"Association pour la Recherche sur les Tumeurs du Rein",{"name":742,"class":743},"Resilience","INDUSTRY",{"name":745,"class":716},"PRIMAA",{"name":747,"class":6},"Queen Mary University of London","100544111","phase-3-care1-pragmatic-clinical-trial-100544111",false,"NCT06364631","CARE1 Pragmatic Clinical Trial","First Line Randomised Study Platform to Optimize Treatment in Patients With Metastatic Renal Cell Carcinoma","CARE1","Inclusion Criteria:\n\n1. Histologically confirmed metastatic (AJCC Stage IV) renal cell carcinoma with a clear-cell component.\n2. Intermediate- or poor-risk mRCC as defined by IMDC classification.\n3. Adult male or female patients (≥ 18 years of age at inclusion).\n4. Karnofsky Performance Status (KPS) ≥70%.\n5. Adequate organ and marrow function, according to investigator assessment and\n\n   1. Absolute neutrophil count (ANC) ≥ 1000\u002FμL (≥ 1.5 GI\u002FL)\n   2. Platelets ≥ 100,000\u002FμL (≥ 100 GI\u002FL)\n   3. Hemoglobin ≥ 8 g\u002FdL (≥ 80 g\u002FL)\n   4. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 5 x ULN.\n   5. Calculated creatinine clearance ≥ 30 mL\u002Fmin (≥ 0.67 mL\u002Fsec) using the CKD- EPI equation\n6. Patient should understand, sign, and date the written informed consent form prior to any protocol-specific procedures performed.\n7. Patient should be able and willing to comply with study visits and procedures as per protocol\n8. Patients must be affiliated to a social security system or beneficiary of the same\n9. Female patients must either be of non-reproductive potential or must have a negative serum pregnancy test within 14 days prior to the administration of study drug. Childbearing potential women must have agreed to use one barrier method of contraception, such as condom, plus an additional highly effective method of contraception during treatment on this trial and for up to 5 months after the last dose of study treatment.\n10. Fertile men with a female partner of childbearing potential must agree to use one barrier method of contraception, such as condom, during treatment on this trial and for up to 4 months after the last dose of treatment. Their women of childbearing potential partner must agree to use a highly effective method of contraception during the same period.\n11. Female subjects of childbearing potential must not be pregnant at screening.\n\nExclusion Criteria:\n\n1. Prior systemic anticancer therapy for mRCC including investigational agents. Note: One prior systemic adjuvant therapy is allowed for completely resected RCC and if recurrence occurred at least 6 months after the last dose of adjuvant therapy.\n2. Uncontrolled brain metastases (adequately treated with radiotherapy and\u002For radiosurgery prior to randomization are eligible). Subjects who are neurologically symptomatic as a result of their CNS metastasis or are receiving systemic corticosteroid treatment (prednisone equivalent \\> 10 mg\u002Fday) at the planned time of randomization are not eligible.\n3. Concomitant oral anti-vitamin K anticoagulation. An exception is the use of LMWH or direct oral anticoagulants (DOAC), if considered safe by investigator assessment.\n4. The subject has uncontrolled, significant intercurrent or recent illness such as the following conditions:\n\n   a. Cardiovascular disorders:\n\n   i. Congestive heart failure (CHF) class III or IV as defined by the New York Heart Association, unstable angina pectoris, myocardial infarction, serious cardiac arrhythmias (e.g., ventricular flutter, ventricular fibrillation, Torsades de pointes).\n\n   ii. Uncontrolled hypertension despite optimal antihypertensive treatment.\n\n   iii. Stroke, or other symptomatic ischemic event or severe thromboembolic event (e.g., symptomatic pulmonary embolism \\[PE\\], incidental PE is acceptable if deemed safe by the investigator) within 3 months before randomization.\n\n   b. Active GI bleeding or symptomatic Gastrointestinal (GI) tract obstruction\n\n   c. Clinically significant bleeding including uncontrolled hematuria, hematemesis, or hemoptysis\n\n   d. Autoimmune disease that has been symptomatic or required immunosuppressive systemic treatment within the past two years from the date of randomization.\n\n   Note: Patients with a history of Crohn's disease or ulcerative colitis are always excluded\n\n   e. Any condition requiring systemic treatment with either corticosteroids (\\> 10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days of randomization.\n\n   Note: Inhaled, intranasal, intra-articular, or topical steroids are permitted. Adrenal replacement steroid doses \\> 10 mg daily prednisone equivalent are permitted. Transient short-term use of systemic corticosteroids for allergic conditions (e.g., contrast allergy) is also allowed.\n\n   f. Active infection requiring systemic treatment.\n\n   g. Major surgery (e.g., nephrectomy, GI surgery, removal of brain metastasis) within 4 weeks prior to randomization or serious non-healing wound\u002Fulcer\u002Fbone fracture.\n5. Pregnant or breastfeeding females.\n6. Any other active malignancy at time of randomization or diagnosis of another malignancy within 3 years prior to randomization that requires active treatment, except for locally curable cancers that have been apparently cured.\n7. Hypersensitivity to any of the active substances or to any of the excipients administered during the study\n8. Use of live vaccines within 28 days before randomization\n9. Persons deprived of their freedom or under guardianship, or for whom it would be impossible to undergo the medical follow-up required by the trial, for geographic, social or psychological reasons.","ALL","18 Years",{"count":759,"type":760},1250,"ESTIMATED","INTERVENTIONAL",[763],"PHASE3","Systemic therapy for renal cell carcinoma (RCC) relies on 2 classes of agents: anti-angiogenic targeted therapy (Vascular endothelial growth factor Tyrosine Kinase Inhibitor- VEGFR TKI) and immune checkpoint inhibitor (ICI), targeting either PD1\u002FPDL1 axis or CTLA4. Combination therapy is SOC for clear cell RCC in all guidelines with either ICI-ICI or ICI-VEGFR TKI. However, no head-to-head comparison have been performed between the 2 approaches and patients are treated based on physician decision without clinical \u002Fbiomarker factors to guide treatment selection. PDL1 staining is, to date, the biomarker that has demonstrated its ability to enrich for overall survival benefit favoring ICI-ICI strategy in PDL1(+) and ICI-VEGFR TKI in PDL1(-) patients.\n\nStudy design has been developed to demonstrate that ICI-ICI is superior to ICI-VEGFR TKI in prolonging Overall Survival (OS) for PDL1(+) patients and to demonstrate that ICI-VEGFR TKI is superior to ICI-ICI in prolonging Progression Free Survival (PFS) and OS for PDL1(-) patients.",[766,767],"Metastatic Kidney Cancer","Metastatic Kidney Carcinoma",[769,770,771,772],"METASTATIC KIDNEY CANCER","METASTATIC KIDNEY CARCINOMA","PRAGMATIC CLINICAL TRIAL","PDL1","2025-01-14",{"date":775,"type":776},"2025-01-16","ACTUAL",{"date":778,"type":776},"2024-04-12",{"date":780,"type":760},"2032-05-05",{"name":5,"class":6},46]